• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
Antivirus agents. Agents used in AIDs treatment. Immunomodulators
Antivirus agents. Agents used in AIDs treatment. Immunomodulators

... Immunomodulators ...
Adverse Drug Reactions to Anti-TB drugs by Dr
Adverse Drug Reactions to Anti-TB drugs by Dr

... • When starting to desensitize it is usually safer to begin with a tenth of the normal dose. Then increase the dose b y a tenth each day, until the patient has the full dose on the tenth day. If the patient has a mild reaction to a dose, give the same dose instead of higher dose next day. If there i ...
annotated bibliography - Michigan State University
annotated bibliography - Michigan State University

... women find that their periods become irregular or stop, while other have found that their periods become heavier and longer. Although MDMA does not produce a physical dependency, some users have become psychologically addicted to it. In order to achieve the same effect soon after, a larger dose has ...
lf you`re fqking rhis drug, don`t eql fhot
lf you`re fqking rhis drug, don`t eql fhot

... Some foods-even goodJor-you ones-con interfere with how certoin medicotions work ...
Neurology Firm NuPathe Gets $15M For Lead Migraine Patch
Neurology Firm NuPathe Gets $15M For Lead Migraine Patch

... data from the ongoing study have so far shown the medication is delivered rapidly and has improved pharmacokinetics over current standards of care. “This will be a 505(b)(2) development plan, so it’s a little bit of a quicker development program than the traditional NDA,” Hollingsworth said. “We exp ...
Chapter 10
Chapter 10

... - PABA is coenzyme used in nucleotide synthesis – these drugs compete for enzyme active site - Humans use folic acid as coenyzme so these drugs do not effect our cells ...
PHARMACOSOMES: OPENING NEW DOORS FOR DRUG DELIVERY  Review Article
PHARMACOSOMES: OPENING NEW DOORS FOR DRUG DELIVERY Review Article

... drugs with precision and selectivity. They help in achieving increased bioavailability, reduce the cost of therapy and provide controlled as well as targeted release of drug. There is reduction in the drug leakage and toxicity while the therapeutic efficacy increases. It is advancing as a method use ...
IOW Dementia MUR Steve Bleakley Nov 2010
IOW Dementia MUR Steve Bleakley Nov 2010

... 6-7% of hospital admissions related to adverse drug reactions Drug interactions account for 1-2% 0.13% are fatal (US data) Around 70% considered avoidable Estimated NHS costs £500million ...
DRUG INTERACTIONS
DRUG INTERACTIONS

... Excessive ethanol intake may lead to hypoglycemia. An “antabuselike reaction” may occur in patients taking sulfonylureas.  Risk factors ...
SKILL SHARPENING TOOLS
SKILL SHARPENING TOOLS

... Alcohol tends to pep up a person because it is a stimulant. Is it true? No. Alcohol is only a depressant. Alcohol’s first action is to depress that part of the brain which controls inhibitions. Since the person becomes less inhibited, he immediately feels more relaxed. But his brain is being depress ...
The Good Hospital Practice Training Series
The Good Hospital Practice Training Series

... D. Forcing functions are the most effective. Policies can be broken. 8. The following is/are reason/s why elderly are more prone to ADEs: a. Old people have trouble remembering their drugs. b. Old people have poor liver and kidney drug handling capacities. c. Old people have lower fat deposits in wh ...
Detection of the pharmaceutical agent glaucine as a recreational drug
Detection of the pharmaceutical agent glaucine as a recreational drug

... 0.7 mg/L should therefore only be considered an approximation. Extended toxicological screening did not detect ethanol or any other drugs, except for cyclizine, which was administered in the ED. Glaucine is an antitussive agent used therapeutically in several countries in the European Union, such as ...
ANTIPSYCHOTIC DRUGS & LITHIUM
ANTIPSYCHOTIC DRUGS & LITHIUM

... Tend to develop after years of therapy May appear as early as 6 months ...
Drug use, Drug abuse and DRUG TAKING BEHAVIOR
Drug use, Drug abuse and DRUG TAKING BEHAVIOR

... weighted interview response rate of 77.0 percent (Table B.3). A total of 9,362 (15.2 percent) sample persons were classified as refusals or parental refusals, 2,918 (3.9 percent) were not available or never at home, and 1,933 (3.9 percent) did not participate for various other reasons, such as physi ...
April 2007 FDA Announces Drug Withdrawals, Recalls
April 2007 FDA Announces Drug Withdrawals, Recalls

... stating that as part of its ongoing efforts to review unapproved marketed drugs and the DESI project, manufacturers will no longer be permitted to produce and distribute suppository forms of trimethobenzamide, a medication typically used for the treatment of nausea and vomiting. These products are a ...
Drug interactions and lethal drug combinations
Drug interactions and lethal drug combinations

... From the Department of Clinical Pharmacology, St Bartholomew's Hospital, London ...
Nursing pharmacology Drugs Affecting Cardiovascular
Nursing pharmacology Drugs Affecting Cardiovascular

... • A 45-year-old man has recently been diagnosed with hypertension and started on monotherapy designed to reduce peripheral resistance and prevent NaCl and water retention. He has developed a persistent cough. • Which of the following drugs would have the same benefits but would not cause cough? • A ...
drug physical symptoms look for dangers
drug physical symptoms look for dangers

... of the world, it is not approved for sale in the United States. It is the most widely prescribed sedative in Europe. Known on the street as rophies, roofies, ruffies, R2, roofenol, roche, and roachies. Rohypnol abuse in the United States was first reported in South Florida in 1993. The street price ...
Pharm_essays_2005_B
Pharm_essays_2005_B

... Most clinically important interactions involve the effect of one drug on the metabolism of another. Drug metabolism involves phase I reactions (oxidation, reduction and hydrolysis) and phase II reactions (conjugation of the drug with other substances). Phase I reactions generally involve the CYP450 ...
Age and Pharmacokinetics Pediatric and Geriatric
Age and Pharmacokinetics Pediatric and Geriatric

... The age-related change in renal clearance is the most consistent and predictable change in pharmacokinetics. The dose of most drugs that are renally cleared should be adjusted for renal function. The adjustment method most frequently used is the Cockroft-Gault equation to estimate renal clearance. T ...
Lecture6- GENERAL PHARMACOLOGY
Lecture6- GENERAL PHARMACOLOGY

... Dr.Abdul latif Mahesar Pharmacology Department ...
150528EN_ASCO Data Release Beleodaq
150528EN_ASCO Data Release Beleodaq

... The assessment included data from a total of 74 patients across four trials: one Phase I/II trial of belinostat in combination with cisplatin, doxorubicin, cyclophosphamide (NCT01100944) and three, single-agent Phase II clinical trials evaluating belinostat (NCT00589290), cixutumumab (NCT00965250) o ...
Document
Document

... large increases in dose can occur over one drug session e.g. crack cocaine binges • however metabolic tolerance dose not develop as rapidly; deaths due to non-CNS effects, especially cardiac or vascular and/or thermoregulatory causes are common. ...
(mg/L) x CL
(mg/L) x CL

... of one formulation against a second (reference) formulation given by the same route. ...
(CNS) Stimulant.
(CNS) Stimulant.

... of pain, loss of bowel or bladder control. ...
< 1 ... 110 111 112 113 114 115 116 117 118 ... 161 >

Orphan drug

An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.In the US and EU it is easier to gain marketing approval for an orphan drug, and there may be other financial incentives, such as extended exclusivity periods, all intended to encourage the development of drugs which might otherwise lack a sufficient profit motive. The assignment of orphan status to a disease and to any drugs developed to treat it is a matter of public policy in many countries, and has resulted in medical breakthroughs that may not have otherwise been achieved due to the economics of drug research and development.According to Thomson Reuters in their 2012 publication ""The Economic Power of Orphan Drugs"", there has been increased investing in orphan drug Research and Development partly due to the U. S. Orphan Drug Act (ODA) 1983 and similar Acts in other regions of the world and also driven by ""high-profile philanthropic funding."" The period between 2001 to 2011 was the ""most productive period in the history of orphan drug development, in terms of average annual orphan drug designations and orphan drug approvals."" For the same decade the compound annual growth rate (CAGR) of the orphan drugs was an ""impressive 25.8 percent, compared to only 20.1 percent for a matched control group of non-orphan drugs."" By 2012 the market for orphan drugs was worth USD$637 million compared to the USD$638 million matched control group of non-orphan drugs, Thomson Reuters.By 2012, ""the revenue-generating potential of orphan drugs [was] as great as for non-orphan drugs, even though patient populations for rare diseases are significantly smaller. Moreover, we suggest that orphan drugs have greater profitability when considered in the full context of developmental drivers including government financial incentives, smaller clinical trial sizes, shorter clinical trial times and higher rates of regulatory success.""
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report